As fears escalate over a potential Ebola outbreak in Central Africa, researchers are racing against time to develop three new vaccines targeting the Bundibugyo strain of the virus, which has already claimed nearly 250 lives. The International Aids Vaccine Initiative (IAVI) is leading one of the initiatives, with support from the University of Oxford and Moderna, as they work to mitigate what could become one of the most severe outbreaks in history.
Growing Outbreak in the Democratic Republic of Congo
Recent reports indicate that the Democratic Republic of Congo (DR Congo) is facing a dire public health crisis, with over 1,000 suspected cases of Ebola and nine confirmed cases spreading into neighbouring Uganda. The outbreak, first detected in a conflict-ridden area with scant healthcare resources, raises alarms that it may rival the catastrophic epidemic observed in West Africa from 2014 to 2016, which resulted in nearly 29,000 infections and over 11,000 deaths.
Dr Mark Feinberg, president and CEO of IAVI, expressed his grave concerns, stating, “This is clearly threatening to be as severe an outbreak as that, if not even worse. The development of a vaccine and other countermeasures is a clear priority.” His sentiments reflect those of Médecins Sans Frontières (MSF), which has described the situation as “deeply alarming,” noting the unprecedented speed at which cases have escalated.
The Need for Targeted Vaccines
Ebola comprises six known species, of which only three are responsible for outbreaks. While an effective vaccine exists for the Zaire species, the current crisis is instigated by the Bundibugyo strain, which has only been recorded in two previous outbreaks and lacks an approved vaccine. IAVI is developing a modified version of the Zaire vaccine aimed specifically at Bundibugyo, which has shown promising results in preliminary tests on monkeys, demonstrating rapid immune response and nearly 100% protection.
Feinberg remains cautiously optimistic about the timeline, estimating that it may take seven to nine months before the vaccine can enter clinical trials, although efforts are underway to expedite this process.
Innovative Approaches from Leading Research Institutions
Moderna has also stepped up to the challenge, leveraging its mRNA technology—successfully employed in the rapid development of COVID-19 vaccines—to create a Bundibugyo vaccine. Stéphane Bancel, the CEO of Moderna, affirmed their commitment to addressing this urgent health crisis: “We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most.”
In parallel, the University of Oxford is employing its own vaccine technology. Their variant is expected to be ready for clinical trials within just two to three months, marking a significant step in the race against the virus.
Different Technologies, Same Goal
Each vaccine in development aims to train the immune system to recognise the Bundibugyo glycoprotein, a key component of the virus’s surface. The methodologies differ: IAVI utilises a live, harmless virus that has been modified to include the Ebola glycoprotein, prompting the immune system to learn to combat the actual virus. Meanwhile, both the mRNA and Oxford vaccines work by introducing a snippet of genetic material that instructs the body to produce the glycoprotein, alerting the immune system to the foreign entity.
While these innovative approaches hold promise, they also necessitate rigorous clinical trials to determine their efficacy, optimal dosage, and overall safety.
Urgent Need for Vaccine Development
Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI), emphasised the urgent need for vaccines, stating, “With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.” Similarly, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, highlighted the potential of a Bundibugyo vaccine to not only control the ongoing epidemic but also bolster preparedness for future outbreaks.
Why it Matters
The urgency of developing effective vaccines against the Bundibugyo strain cannot be overstated, especially as the current outbreak unfolds in a region with limited healthcare infrastructure. The international community’s response, bolstered by innovative research and collaborative efforts, is crucial for not only curbing this outbreak but also for safeguarding against future Ebola threats. The stakes are high, and with lives hanging in the balance, every advancement in vaccine development represents a beacon of hope in the face of this formidable virus.
